Clinical trial
A Study Evaluating IV Oncaspar® and IV Gemzar® in the Treatment of Solid Tumors…
NCT00363610 · Enzon Pharmaceuticals, Inc., Industry · Terminated
Key facts
| NCT number | NCT00363610 |
|---|---|
| Title | A Study Evaluating IV Oncaspar® and IV Gemzar® in the Treatment of Solid Tumors and Lymphoma |
| Official title | A Multicenter, Open-Label, Phase I Study Evaluating the Safety and Tolerability of Intravenous Pegaspargase in Combination With Intravenous Gemcitabine HCl in the Treatment of Advanced and/or Metastatic Solid Tumors and Lymphoma |
| Lead sponsor | Enzon Pharmaceuticals, Inc., Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Tumors, Lymphoma |
| Intervention type | Drug |
| Interventions | Oncaspar & Gemzar, advanced and/or solid tumors and lymphoma |
| Enrollment | 19 |
| Start date | Jul 1, 2006 |
| Primary completion | Nov 1, 2007 |
| Completion | Jun 1, 2008 |
| First posted | Aug 15, 2006 |
| Last update posted | May 20, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: